We are committed to delivering next-generation cancer therapies.
Coherus is focused on developing and commercializing a diversified portfolio of next-generation immuno-oncology therapies that potentially extend patient survival across tumor types. The approval of LOQTORZI™ (toripalimab-tpzi) and the advancement of multiple clinical stage immuno-oncology candidates targeting the tumor microenvironment underscore our commitment to immuno-oncology while the established infrastructure of our biosimilar business enables us to provide better treatment access and outcomes for patients with life-altering illnesses.
The approval of LOQTORZI and our diversified pipeline of clinical-stage immuno-oncology candidates targeting the tumor microenvironment underscore our commitment to advancing immuno-oncology treatments.
For more than a decade, the Coherus team has worked alongside each other across multiple disease areas to successfully develop and commercialize our biosimilars product portfolio. We are now focused on advancing novel immuno-oncology treatments with the same commitment to patients and our team’s proven success in development and commercialization.